COMPASS Pathways plc (CMPS)

Market Cap	858.63M +232.1%
Revenue (ttm)	n/a
Net Income	-287.86M
EPS	-3.08
Shares Out	128.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,962,384
Open	6.80
Previous Close	6.66
Day's Range	6.55 - 6.95
52-Week Range	2.25 - 8.90
Beta	2.02
Analysts	Strong Buy
Price Target	26.57 (+298.95%)
Earnings Date	May 7, 2026

About CMPS

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in L...

• Industry: Medical Care Facilities
• Sector: Healthcare
• IPO Date: Sep 18, 2020
• Employees: 156
• Stock Exchange: NASDAQ
• Ticker Symbol: CMPS
• Website: https://compasspathways.com

Analyst Summary

According to 7 analysts, the average rating for CMPS stock is "Strong Buy." The 12-month stock price target is $26.57, which is an increase of 298.95% from the latest price.

Price Target

$26.57

(298.95% upside)

Analyst Consensus: Strong Buy